Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …

… John PH Wilding … John PH Wilding … Sosenko, John PH Wilding, Robert E. Ratner;
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes 1 February …

This paper considers the argument for obesity as a chronic relapsing disease process. Obesity
is viewed from an epidemiological model, with an agent affecting the host and producing …

Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose
cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Background Obesity is a chronic disease with serious health consequences, but weight loss
is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide…

Aims Obstructive sleep apnoea (OSA) is associated with increased cardiovascular morbidity
and mortality. Although it was previously assumed that this was due to its relation with …

Background Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In …

A modern approach to obesity acknowledges the multifactorial determinants of weight gain
and the health benefits to be derived from weight loss. Foundational to any weight loss effort …

SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …